Top-Line Results For Sanofi/Genzyme's MS Drug Lemtrada Leave Investors Wanting More

Alemtuzumab scores a win in reducing relapse rates, but doesn't best interferon beta-1a at preventing disability in first of two crucial Phase III studies due to report this year.